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OBJECTIVES: Steroids are used to induce remission in autoimmune pancreatitis (AIP). Low-dosage steroid therapy or
immunosuppressant (IMs) has been proposed as maintenance therapy to prevent AIP relapse. Few and conflicting data have been
published on the efficacy of azathioprine (AZA) in preventing AIP relapse. The aim of this study was to evaluate the indication and
efficacy of AZA as maintenance therapy to prevent disease relapse in AIP.
METHODS: Patients suffering from AIP diagnosed according to the ICDC in type 1, type 2, and not otherwise specified (NOS) were
divided in those treated with AZA (AZA+ group) as maintenance therapy and not treated with maintenance therapy (AZA− group).
Exclusion criteria were: previous pancreatic surgery, other autoimmune diseases as indication for AZA treatment, and use of IMs
different from AZA. Drug safety, clinical and instrumental outcome of AZA+ patients were evaluated.
RESULTS: A total of 23 patients (18 Males and 5 Females, mean age 54± 11 years) in AZA+ group and 97 (58 Males and 39 Females,
mean age 45± 18 years) in AZA− group were compared. In AZA+ group, patients were significantly older (P= 0.043), type 1 AIP
was more frequently diagnosed (87 vs. 51%, P= 0.006), sIgG4 higher (758± 625 vs. 311± 409 mg/dl, Po0.001), other organ
involvement (OOI) more frequently observed (83 vs. 48%, P= 0.002), with higher frequency of relapse before AZA treatment (78 vs.
14%, Po0.001). Three patients in AZA+ group required drug discontinuation because of adverse events. Twenty patients were
therefore evaluated for outcome. Six out of 20 patients (30%) relapsed after 24± 15 months (5 in pancreas and 1 on biliary tract).
They were retreated with steroids and continued AZA. Two out of 6 patients (33%) had a second relapse,after respectively
11 months (in pancreas and kidney) and 22 months (in kidney).
CONCLUSIONS: AZA is an effective and safe treatment to prevent AIP relapses.
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INTRODUCTION
Autoimmune pancreatitis (AIP) is a particular form of
pancreatitis with unique histological features.1,2 Two histolo-
gical subtypes in AIP have been recognized with different
clinical profiles.2–5 Type 1 AIP is characterized by periductal
infiltration of lymphocytes, abundant IgG4-positive plasma
cells in pancreatic parenchyma, storiform fibrosis and oblit-
erative phlebitis. Patients suffering from type 1 AIP are elderly,
with a prevalence of male sex, with high IgG4 serum levels,
extra pancreatic involvement (biliary tree, salivary glands,
kidney, retroperitoneum), and frequent relapses. Type 2 AIP is
characterized by the presence of granulocytic epithelial
lesions, whereas IgG4-positive plasma cells are rare or absent
in pancreatic parenchyma. Patients suffering from type 2 AIP
are younger, inflammatory bowel disease is commonly
observed, and relapses after steroids are rare.
The International Association of Pancreatology in 2011
defined the International Consensus Diagnostic Criteria (ICDC)
based on five cardinal features (parenchymal and pancreatic
duct imaging, serology, other organ involvement, histology, and
response to steroid) categorized as level 1 and 2 of evidence
according to their reliability to diagnose AIP.6 These criteria are
able to diagnose AIP subtypes also in the absence of histology,
and introduced criteria for AIP not otherwise specified (NOS), if
type 1 and type 2 AIP cannot be diagnosed.
A dramatic response to steroid therapy has been reported in
AIP, independently from the subtype.7–9 However, a significant
proportion of patients (15–60%) develop disease relapse after
steroids, more frequently those suffering from type 1 and NOS
AIP compared to type 2 AIP.7–10 There is no consensus on
indications, type and duration of maintenance therapy
because no prospective randomized controlled trials have
been published yet. To prevent recurrences low-dosage long-
term steroid therapy (that is, prednisone 2.5–10 mg up to
3 years) after induction of remission has been proposed
mainly by Japanese authors,11 whereas immunosuppressant
drugs (azathioprine [AZA], 6-mercaptopurine, mycophenolate
mofetil) have been suggested in Western countries to avoid
the side effects of steroids.12,13 Few studies report the
efficacy of immunosuppressants as maintenance therapy
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for AIP.8,14–17 A study fromMayoClinic shows no differences in
relapse-free survival in patients treated with immunosuppres-
sants and steroids compared to steroids alone.17 In the same
study, rituximab (RTX), an anti-CD20 antibody, seems to be
effective in 12 patients in steroid-dependent or intolerant, and
resistant to immunosuppressants. A recent UK multicenter
study in patients suffering from IgG4-related disease involving
the pancreas (92%) shows that in 41 patients treated by AZA,
13 were intolerant and only eight of the remaining (28%) had a
disease relapse.18 Furthermore, none of AZA treated patients
need to be retreated with steroids or RTX.
The aim of this study was therefore to evaluate indication,
efficacy and safety of AZA as maintenance therapy in patients
suffering from AIP.
METHODS
We retrospectively reviewed the AIP database in our Depart-
ment on January 2014. We included patients with a diagnosis
of AIP based on ICDC6 and patients were therefore classified
in type 1, 2, and NOS. Exclusion criteria were: (1) pancreatic
surgery; (2) use of an immunosuppressant different from
azathioprine; (3) indication for the use of azathioprine different
from AIP. Patients were then divided into those treated with
AZA as maintenance therapy (AZA+ group) and those not
treated (AZA− group).
The demographic data (sex, age at presentation, alcoholic
consumption, smoking habits), symptoms and signs at clinical
onset (weight loss, pancreatitis, jaundice, steatorrhea, dia-
betes), radiological (CT, MRI) findings (focal and diffuse
involvement of the pancreas, abdominal extra pancreatic
involvement), serum IgG4 (sIgG4) levels, fecal elastase 1,
steroid treatment were evaluated. Salivary gland involvement
was based on clinical examination.
The upper normal limit of sIgG4 levels was considered
135 mg/dl, as previously reported by Hamano et al.19
Prednisone was administered at initial dose of 1 mg/kg of
body weight per day for 2–4 weeks and then tapered by 5 mg
every week up to suspension.
Relapsing AIP was defined as development of pancreatic
and/or extra pancreatic alterations at imaging.20,21 In parti-
cular, sIgG4 elevation alone was not considered disease
relapse.
AZA is generally used in our Department after a first or
second relapse in AIP patients or in AIP patients with a high
risk of relapse (other organ’s involvement and/or high IgG4
levels). After recurrence, patients were re-treated with another
course of prednisone. In those treated with AZA, the
immunosuppressant was added after starting the steroid
course, and maintained after steroids withdrawal.
Tuberculosis, cytomegalovirus, Epstein–Barr, hepatitis B
and C screening prior to treatment with AZA was evaluated in
all patients. AZA was started at 25–50 mg per day and
increased by 25 mg every 3–7 days after regular monitoring
the biochemical data (peripheral blood counts, pancreatic,
kidney, and liver serum tests). The target dose was 2–2.5 mg/
kg per day, and monthly laboratory test were routinely
performed. AZA withdrawal was decided by physician when
adverse drug reactions occurred, or in the presence of altered
laboratory tests after an attempt of dose reduction. All patients
underwent CT or MRI imaging 3–6 months after steroid and
AZA introduction and then yearly, as protocol in our Institution.
Further imaging assessments were performed depending on
clinical and biochemical evaluation.
Outcome of patients treated with AZA was then assessed.
Pancreatic exocrine function was also evaluated in AZA+
group before AZA initiation and after at least 6 months of
immunosuppressant therapy by fecal elastase 1.
Patients without a radiological detection in the last 3 years
were considered drop-out. The end of follow-up was
January 2014.
Kruskal–Wallis test and Mann–Whitney U-test were used to
analyze the non parametric data.
Fisher’s exact test and χ2 test were used for discrete
variables as appropriate. Survival curve was used to evaluate
relapses during AZA therapy.
Spearman’s rank-order correlation was used tomeasure the
strength of association between serum IgG4 levels before and
after steroids, and after steroids and after AZA.
A P-valueo0.05 was considered significant. Mean and s.d.
are reported. Statistic was processed using the SPSS 17
statistical program (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 165 patients were in our database of AIP on January
2014. Forty-five patientswere excluded from this study (13 could
not be classified according to the ICDC, 21 underwent
pancreatic surgery, eight had other autoimmune diseases as
indication for AZA treatment and three were treated with other
immunosuppressants). A total of 120 patients were therefore
included in the present study and divided in those treated with
AZA (AZA+ group) as maintenance therapy and those not
treated (AZA− group). Twenty-three patients in AZA+ group
(18 Males and 5 Females, mean age 54±11 years, 20 type 1
AIP and 3 AIP-NOS) and 97 in AZA− group (58 Males and 39
Females, mean age 45±18 years, 50 type 1 AIP, 19 type 2 AIP
and 28 AIP-NOS) were compared. The characteristics of these
two groups are summarized in Table 1.
In AZA+ group, patients were significantly older (P=0.043),
type 1 AIP was more frequently diagnosed (87 vs. 51%,
P= 0.006), sIgG4 higher (758± 625 vs. 311±409 mg/dl,
Po0.001), other organ involvement (OOI) more frequently
observed (83 vs. 48%, P=0.002). AIP relapse was observed
in 18 patients (78%) before AZA treatment in AZA+ group and
in 14 patients (14%) in AZA− group (Po0.001).
The indications for the maintenance therapy with AZA were
relapse of AIP in 18 patients (78%), extra pancreatic
involvement in 3 (13%, 1 proximal bile duct stricture and 2
renal lesions) and markedly increase of serum IgG4 after
steroid treatment in 2 (9%).
Three patients (13%) required AZA discontinuation
within two months after starting because of adverse events:
hepatitis (1 patient, then treated with RTX), anaphylactic
shock (1 patient, then treated with maintenance dose of
5 mg per day of oral prednisone), nausea and body weight
loss (1 patient who then refused AZA dose reduction and
re-challenge).
Twenty patients were therefore evaluated for outcome
(15 Males and 5 Females mean age 53±10.8 years, 18 type
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1 AIP and 2 AIP-NOS). Mean duration of treatment was
35.6±21.3 months and AZA dose was between 2 and
2.27 mg/kg per day. Figure 1 summarized the results of AZA
treatment.
Fourteen out of 20 patients (70%) reached and maintained
complete disease remission during follow-up (30±20.2
months), while 6 out of 20 (30%) relapsed after
24± 15.4 months. Five patients had disease relapse in
pancreas and 1 in biliary tract. Relapse-free survival from
the beginning of AZA treatment to the first relapse under
immunosuppressant therapy is shown in Figure 2. Median
relapse-free survival time was 47 months.
The proportion of subjects having a relapse was similar in
those with and without biliary involvement (22 vs. 36%,
respectively, P=ns). Disease relapse was not correlated with
focal or diffuse pancreatic involvement at diagnosis (33 vs.
27%, respectively, P=ns). None of the four patients with only
pancreatic involvement had a relapse during AZA treatment
compared with 6 out of 16 with other organ involvement (38%),
but this difference did not reach the statistical significance.
Moreover, none of the four patients with normal serum IgG4 at
onset but 6 out of 14 (43%) with abnormal serum IgG4 levels at
onset had a relapse, but also this difference was not
significant.
Patients who presented recurrences were all retreated with
another course of steroids followed by complete tapering and
continued AZA therapy. Two out of six patients (33%) had a
second relapse after respectively 11 months (in pancreas and
kidney) and 22 months (in kidney) and are in screening for
RTX treatment. The other four patients did not have a second
relapse after a mean follow-up time of 19± 10 months. Serum
IgG4 levels in AZA+ group were higher at onset compared with
those detected after steroids and before the AZA treatment
(764±675 mg/dl vs. 435±272 mg/dl, respectively,P=0.006).
We found a correlation between sIgG4measured at onset and
before AZA treatment (R=0.797, Po0.0001) (Figure 3).
Serum IgG4 levels were significantly higher in patients before
AZA treatment comparedwith those detected almost 6months
after AZA treatment (435±272 vs. 225± 155 mg/dl, respec-
tively, P=0.003). sIgG4 measured before and after AZA
treatment were significantly correlated (R=0.684, P= 0.002)
(Figure 4).
Sixteen out of 20 patients underwent determination of
fecal elastase 1 before AZA treatment and after almost
6 months later. Fecal elastase 1 was significantly lower in
these 16 patients before AZA treatment (109.2± 98.8 mg/dl)
than after (270.8±156.7 mg/dl) (P= 0.002). No modification
on diabetic status was observed before and after AZA
treatment.
No malignancy has been observed in AZA treated patients.
Among the 97 AZA- patients, 14 experienced a relapse of
the disease. Among these, 5 (including 3 patients with 41
relapse) refused AZA, one had a recent breast cancer treated
with chemo- and radio-therapy, and eight were retreated with
steroids after the first relapse without experiencing additional
relapses.
DISCUSSION
The results of this study seem to show the efficacy and safety
of AZA maintenance therapy in AIP.
The conflicting and retrospective data have been published
on the efficacy of AZA in the treatment of AIP14–17 depend-
ing on limited number of patients, indications, inclusion/
exclusion criteria, dose and duration of therapy, definition of
disease relapse.
In the current study, we excluded patients who underwent
pancreatic surgery because partial pancreatectomy has been
suggested as an effective therapeutic approach for AIP.22–24
We excluded also subjects with other autoimmune diseases
different from AIP as indication for AZA treatment, and those
treated with other immunosuppressants (methotrexate,
cyclosporine and mycophenolate mofetil), suggested or used
in previous studies.25,26 Indeed, the main end point of this
study was to clarify the efficacy of AZA for AIP and not
immunosuppressant at all.
Table 1 Characteristics of AZA+ group and AZA− group
Parameter AZA+ AZA− P
N 23 97 –
Male sex 18 (78%) 58 (60%) ns
Age at onset (years) 54±11 45± 18 0.043
Follow-up (years) 4.9±4.1 2.7±3 0.005
Drop-out 0% 15% 0.07
Drinkers 4/21 (19%) 27/93 (29%) ns
Smokers 5/21 (24%) 24/92 (24%) ns
AIP type (according to the ICDC)
Type 1 AIP 20 (87%) 50 (51%) 0.006
Type 2 AIP 0 19 (20%)
AIP-NOS 3 (13%) 28 (29%)
Enlargement of pancreas
Focal 11 (48%) 53 (55%) ns
Diffuse 12 (52%) 44 (45%)
Symptom at clinical onset
Acute pancreatitis 3 (13%) 27 (28%) ns
Jaundice 18 (78%) 35 (36%) o0.0001
Body weight loss 20/22 (91%) 63/92 (68%) 0.035
Diabetes 4 (17%) 10 (10%) ns
Steatorrhoea 1 (4%) 5 (5%) ns
Elevated sIgG4 at onset
(4135 mg/dl)
17/21 (74%) 42/84 (50%) 0.013
sIgG4 at onset (mg/dl) 758±625 311± 409 o0.001
Other organ involvement
(OOI)
19 (83%) 47 (48%) 0.002
Bile duct 12 (52%) 17 (17%) o0.0001
Kidney 8 (35%) 4 (4%) o0.0001
Salivary glands 4 (17%) 3 (3%) 0.025
Colon 1 (4%) 26 (27%) 0.024
Retroperitoneal fibrosis 0 4 (4%) ns
41 5 (22%) 7 (7%) 0.052
Steroid treatment at
clinical onset
23 (100%) 91 (94%) ns
Recurrencesa
0 5 (22%) 83 (86%) o0.0001
1 13 (56%) 11 (11%)
41 5 (22%) 3 (3%)
AIP, autoimmune pancreatitis; AZA, azathioprine; ICDC, International Con-
sensus Diagnostic Criteria; NOS, not otherwise specified; ns, not specofied.
aFor AZA+ group only recurrences before immunosuppressant treatment were
considered.
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We retrospectively studied AZA+ group patients compared
with AZA− group to evaluate the indications for AZA in our
Center. The results show that patients with type 1 (n= 20) and
NOS (n=3) AIP, but not with type 2 AIP, were treated with AZA,
according to previous studies showing a higher disease
relapse rate after steroids in type 1 and NOS AIP.3,4,7,10,17
All the other features differentiating the two groups are related
to this data. Indeed, patients treated with AZA were older,
showed more often an elevation of serum IgG4, had more
frequently disease relapses, and presented more often extra
pancreatic involvement. Therefore, type 1 AIP patients with
extra pancreatic involvement and serum IgG4 elevation, have
a higher probability to be treated with AZA. This clinical profile
seem to identify patients with an IgG4-related disease.27
AZA treatment seems to be effective as maintenance
therapy of AIP since 70% of patients treated with AZA did
not showdisease recurrence in amean follow-upof 30months.
Survival curve for disease relapse shows that 75% of treated
patients maintained remission up to 36 months. This evidence
is even more significant since patients treated have a more
aggressive disease and AZA can keep in remission a
noteworthy proportion of them for a long time. We observed
also a decrease of sIgG4 levels after steroid treatment and a
further decrease after AZA treatment in AZA+ group, aswell as
a significant improvement of the exocrine pancreatic function
Figure 1 Summary of the outcome in 23 patients treated with AZA.
Figure 2 Relapse-free survival curve for AIP patients treated with AZA.
Figure 3 Correlation between sIgG4 before steroids and after steroids/before
AZA in 18 patients of AZA+ group.
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evaluated with fecal elastase 1 after AZA treatment. These
surrogate laboratory data support the efficacy of AZA as
maintenance therapy in AIP.
These results are in accordance with a recent multicenter
study from UK in the use of AZA in IgG4-related disease,
involving in 92% of case the pancreas, where AZAwas able to
maintain 20 out of 28 patients (71%) in remission, excluding
those intolerant to the drug.18
Disease relapses during AZA treatment were observed in
all but one patient mainly in the pancreas. We therefore
suggest to schedule an imaging follow-up in patients with
AIP treated with AZA. We did not find predictive factors of
disease relapse, probably due to the small sample size
(n= 20). However, extra pancreatic organ involvement and
high sIgG4 before may be predictor factors of disease relapse
during AZA treatment, but other studies are needed to confirm
this data.
We observed three adverse effects (13%), leading to drug
discontinuation. This rate is similar to that observed in the AZA
treatment of other gastrointestinal autoimmune diseases.28
Furthermore, no acute pancreatitis has been observed in our
cohort. Therefore, despite acute pancreatitis is described in
AZA-treated patients,29 these results seems to suggest the
safety of AZA therapy in AIP.
Recently, some studies suggested a risk to develop extra
pancreatic neoplasia in AIP17,30,31 (10%within the first 5 years
from AIP diagnosis), and it is still debated if it is increased
compared with the general population or only age-related. In
any case, AZA treatment may further increase this risk, as
suggested in other gastrointestinal inflammatory disease
(that is, IBD). However, a maintenance therapy with low dose
of steroids leads to adverse effects, particularly in the elderly
(osteoporosis, diabetes). Therefore, a maintenance therapy
should be evaluated considering the risk-benefit balance of
these different approaches, and the previous diagnosis of any
cancer.
Patients who presented a second relapse during AZA
maintenance therapy were re-treated with steroids, contin-
uing the immunosuppressant, and only two patients had
a further relapse. This approach was forced since biologics
(RTX) were not available. Indeed, the use of RTX in AIP
has not been yet approved by the Italian Drug Agency (AIFA)
and it must be justified as off-label for single patient on
the basis of a recent study in 12 patients by Mayo Clinic. The
possible use of biologics will introduce also in AIP the
possibility of a step-up vs. a top down approach, similarly to
other inflammatory chronic disease (that is, Crohn disease).
Applying forcedly a step-up approach (steroid→AZA→RTX),
only a limited proportion of them may have an indication
for RTX (three AZA intolerant and six relapsing in
AZA). Considering this low number of patients, the high
cost of RTX and the absence of randomized controlled
trial, we believe that a step-up approach should be preferred
in presence of a 30% relapse rate observed in our AIP
patients.
The immediate administration of AZA concomitant to the
steroid therapy and prolonged after steroid withdrawal
(“primary maintenance therapy”) may be considered in
untreated patients with a high risk of recurrence such as
patients with high serum IgG4 and patients with other organ’s
involvement (especially biliary tree). However, the definitive
data supporting this strategy are lacking.
A critical issue not yet clarified is how long we can
treat AIP patients with AZA. Our behavior is to try to stop
AZA after a 5-year treatment, similar to that suggested in
Crohn’s disease, even considering that this approach
exposes AIP patients to disease relapse. However, this
approach is only theoretical, and need to be confirmed by
future studies.
The main limitation of the present study is the lack of an
appropriate relapsing type 1 AIP control group. This is
consequence of the retrospective nature of the study.
However, future prospective studies focused mainly on
relapsing type 1 AIP patients might investigate this aspect.
In conclusion, AZA seems to be effective to prevent disease
relapse and safe as maintenance therapy in patients suffering
from AIP. Prospective randomized trials are necessary to
confirm these retrospective data.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Autoimmune pancreatitis is a well-defined clinical entity.
✓ Steroid treatment is effective to induce disease remission.
✓ Low-dosage steroids, immunosuppressant or rituximab
have been proposed as maintenance therapy for
autoimmune pancreatitis.
✓ Conflicting results have been published on the efficacy of
azathioprine tomaintain remissiononautoimmunepancreatitis.
WHAT IS NEW HERE
✓ Azathioprine is a safe and effective treatment to maintain
remission in autoimmune pancreatitis.
✓ The use of azathioprine (AZA) may be considered in
relapsing type 1 autoimmune pancreatitis (AIP) and/or in
the presence of other organ’s involvement and elevated
IgG4 at clinical onset.
✓ A step-up approach (steroids, azathioprine, rituximab) can
be proposed in autoimmune pancreatitis.
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